BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34581783)

  • 21. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Characteristics and Prognosis of U2AF1 Mutation in Patients with Acute Myeloid Leukemia].
    Zhao TY; Guan LX; Zheng WS; Wang ML; Cheng LC; Hu YL; Xu YY; Gu ZY; Dou LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):7-11. PubMed ID: 32027245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
    Bamopoulos SA; Batcha AMN; Jurinovic V; Rothenberg-Thurley M; Janke H; Ksienzyk B; Philippou-Massier J; Graf A; Krebs S; Blum H; Schneider S; Konstandin N; Sauerland MC; Görlich D; Berdel WE; Woermann BJ; Bohlander SK; Canzar S; Mansmann U; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T
    Leukemia; 2020 Oct; 34(10):2621-2634. PubMed ID: 32358566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome].
    Zhao WS; Zhang YT; Jiang QL; Liu QF; Dai M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1977-1984. PubMed ID: 33283729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
    Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
    Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
    Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.
    Six KA; Gerdemann U; Brown AL; Place AE; Cantor AB; Kutny MA; Avagyan S
    Blood Adv; 2021 Aug; 5(16):3199-3202. PubMed ID: 34424323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
    Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
    Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
    Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
    Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal architecture of secondary acute myeloid leukemia.
    Walter MJ; Shen D; Ding L; Shao J; Koboldt DC; Chen K; Larson DE; McLellan MD; Dooling D; Abbott R; Fulton R; Magrini V; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Fan X; Grillot M; Witowski S; Heath S; Frater JL; Eades W; Tomasson M; Westervelt P; DiPersio JF; Link DC; Mardis ER; Ley TJ; Wilson RK; Graubert TA
    N Engl J Med; 2012 Mar; 366(12):1090-8. PubMed ID: 22417201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased CD177
    Alayed K; Meyerson HJ
    Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Pathogenic
    Förster A; Decker M; Schlegelberger B; Ripperger T
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022.
    Bouligny IM; Maher KR; Grant S
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
    Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
    J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
    Akef A; McGraw K; Cappell SD; Larson DR
    PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.